#India #Mumbai #Lupin #Tenpoint #YUVEZZI

Lupin and Tenpoint Therapeutics Join Forces for YUVEZZI™ Commercialization in Europe

In a significant announcement from Mumbai, Lupin Limited, a prominent global pharmaceutical company, has declared its strategic partnership with Tenpoint Therapeutics to commercialize YUVEZZI™, a groundbreaking once-daily eye drop for presbyopia. This collaborative effort targets the European Union, the United Kingdom, Switzerland, Norway, and Iceland, key regions where access to innovative eye care solutions is pivotal.

Strategic Partnership Overview

Under this exclusive licensing agreement, Lupin's subsidiary VISUfarma will handle regulatory activities, marketing, promotion, distribution, and sales of YUVEZZI™ in these licensed territories. YUVEZZI™, a dual-agent formulation consisting of carbachol and brimonidine tartrate, has already been recognized for its potential to improve near vision for adults experiencing presbyopia as they age.

This partnership comes with a commitment to invest strategically in the commercial landscape. Tenpoint Therapeutics will benefit from regulatory and commercial milestone payments, along with tiered royalties based on net sales. This collaboration not only enhances YUVEZZI™'s market presence but also reflects Lupin's ongoing ambition to advance patient access across the continent.

Commitment to Innovate

Vinita Gupta, CEO of Lupin, expressed enthusiasm about this collaboration, emphasizing its alignment with the company's strategy to expand its specialty care portfolio. “Partnering with Tenpoint Therapeutics allows us to leverage innovative eyecare therapies that can significantly improve patient outcomes. YUVEZZI™ strengthens our existing vision care franchise and reaffirms our leadership in the eye care market,” she remarked.

Henric Bjarke, CEO of Tenpoint, echoed this sentiment, highlighting the importance of making YUVEZZI™ accessible to millions suffering from presbyopia and the significant role Lupin plays due to its strong commercial operations in Europe.

The Significance of YUVEZZI™

YUVEZZI™ has gained attention as the first approved once-daily dual-agent eye drop for presbyopia, offering a much-needed solution for the approximately 128 million individuals affected by this condition in the U.S. alone. The formulation combines the agents carbachol and brimonidine to effectively manage vision in those impacted by aging.

As both companies move forward, Tenpoint is already in the midst of commercializing YUVEZZI™ in the United States, having received FDA approval. This robust partnership signifies a mutual commitment to address unmet patient needs in eyecare through novel and impactful therapies.

Expanding the Vision Care Landscape

Lupin has established a solid presence within the pharmaceutical industry, maintaining a diverse portfolio that includes generics and specialized medications. The company’s operations span major markets, with a focus on improving healthcare access through innovative therapies. The contribution of YUVEZZI™ to their ophthalmology portfolio is a testament to Lupin's dedication to addressing significant health challenges.

As the demand for effective vision management solutions grows, this partnership is poised to elevate the standard of care available for presbyopia, reflecting both companies' commitment to pioneering advancements in eyecare globally.

In summary, the partnership between Lupin and Tenpoint Therapeutics signifies a proactive step towards enhancing the availability of innovative ophthalmic treatments in Europe, promising improved vision care solutions for aging populations. Together, they are set to make a substantial impact on the presbyopia management segment, reinforcing their positions as leaders in the pharmaceutical landscape.